New TaqMan & SYBR Green Fast Advanced Cells-to-CT Kits provide a faster and more sensitive way to measure gene expression
CARLSBAD, CA, UNITED STATES - Jun 18, 2018 - Thermo Fisher Scientific
Inc.
, the world leader in serving science, today announced the launch of its new Invitrogen TaqMan & SYBR Green Fast Advanced Cells-to-CT Kits, further strengthening its line of RNA Cells-to-CT products. With the Fast Advanced Cells-to-CT Kits, researchers will experience a faster reverse transcriptase reaction and have access to a qPCR master mix system fully optimized to improve sensitivity to detect rare transcripts. This makes it possible to perform high-throughput expression analysis directly from cultured cells without RNA purification and without risking sensitivity.
We are committed to accelerating sample to answer for our customers performing gene expression studies and are excited that we can now offer customers an even faster, more sensitive workflow to measure relative gene expression through real-time RT-PCR without having to purify RNA prior to amplification, said Ole Dahlberg, vice president and general manager of sample preparation at Thermo Fisher Scientific. The latest offering in our portfolio of RNA Cells-to-CT kits offers researchers the fastest workflows to date and higher sensitivity and detection of abundant and rare transcripts. These kits help save time and offer a simple workflow that is suitable for a few samples, but can also be easily incorporated into automated, high-throughput applications, said Dahlberg. Researchers can now focus on higher value activities - such as analyzing high-throughput drug screening data or performing supplementary genome editing or silencing validation studies.
As with previous Cells-to-CT kits, the Fast Advanced Cells-to-CT Kits employ a five-minute lysis system to quickly lyse cultured cells while simultaneously removing genomic DNA (gDNA) and preserving RNA integrity. The proprietary Cells-to-CT Stop Solution irreversibly terminates the lysis reaction enabling users to carry the most sample into the RT and qPCR reactions to maximize the detection of RNA transcripts. Detecting rare RNA transcripts in low-input cell samples (10-1,000) is higher when samples are processed with Cells-to-CT kits compared to results from the same samples using RNA purification workflows. Now, the new Fast Advanced Cells-to-CT Kits are fully optimized with updated reverse transcription (RT) reagents for cDNA synthesis and faster TaqMan or SYBR Green master mixes for real-time PCR analysis.
For more information about the new Invitrogen Fast Advanced Cells-to-CT Kits or other or other Cells-to-CT kits and gene expression analysis solutions, visit
thermofisher.com/cellstoct
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands - Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services - we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit
thermofisher.com
.